Bibilography
1) Total population death rate for CVD by age, per 100000, US, 1979-93. Dallas, Tex : American Heart Association, 1996.
2) . Murray CJL, Lopez AD. The global burden of disease : Summary, Cambridge, Mass : Harvard University Press; 1996.
3) Armstrong VW, Cremer P, Eberie E et al. The association between serum lp(a) concentration and angiographically assessed coronary atherosclerosis Dependence on serum low density lipoprotein level. Atherosclerosis. 1986: 62: 249-57
4 Hughes LO, Raval U, Raftery EB: First myocardial infarction in Asian Indians and white men. BR Med J 298 :1345-1350, 1989.
5 Litter WA, Lawrence PE. Acute myocardial infarction in Asian Indians and whites in Birmingham. BR Med J 290: 1472,1985.
6 Scanu AM, Lawn AM, Berg K. Lipoprotein (a) and atherosclerosis Ann Internal Medicine. 115: 209-218,1991
7 Jenkins AJ, Steele JS, Yunus ED, Santamaria JD, Best JD : Plasma apo lipoprotein (a) is increased in type 2 diabetic patient with micro albuminuria. Diabetologea 35 : 1055 - 1059, 1992.
8 Hearn JA, De Maio SJ (Jr), Roubin GS, Hammarstrom M, Sgoutas D : Predictive value of lipoprotein (a) and other serum lipo proteins in the angiographic diagnosis of CAD. AM J Cardiol 66 : 1176 - 1180, 1990.
9 Mohan V, Raj Deepa, Sai Prashanth, Gopal Premlatha. Lipo protein (a) is an independent risk factor for coronary artery disease in NIDDM patients in South India.
10 Sainani G.S et al. Dyslipdemias and coronary artery disease (Indian Context) In : Das AK, Medicine update 1998; 8 : 560 - 3.
11 Chandrika R, Mohan V:Cardiovascular risk factors in Indian NIDDM patients;Novo Nordisk Diabetes Update 5th proceedings p43.1996.
12 Malhotra SL - Epidemiology of ischemic heart disease in India with special reference to caucasians; Brit. Heart J. 1967, 29 : 895 - 905.
13 Enas EA, Yusuf S, Mehta JL, Prevalence of CAD in Asian Indians Am J. Cardiol. 1992, 70 : 945 - 949.
3)
4)
5)
6)
7)
8)
9)
10)
11)
12) D C Ghosh, Roy S:NIDDM and CAD-a lipid connection.Lipid India p15-17,1999.
13) Das S.Lipid profiles-standards and interpretations.In Kapur A Ed NNDU-95 Proceedings Health Care.Communication,Bombay,1995 P107-118
14) Medina JL.The role of lipoprotein in the devolepment of arterial disease in diabetics.Diab-Lit Rev Serv 1994;4:11-15.
15) Laker FM.Plasma lipids and lipoproteins in diabetes mellitus.In Alberti KGMM,Krall LP Eds. The diabetes annual vol: Elsevier,Amsterdam 1986;267-282
16) Nikkila EA, HDLc in diabetes. Diabetes 1981;30(Suppl.2):82-87.
17) Eder HA and Gidez LI.The clinical significance of plasma HDLc.Med Clin of North America 1982;66(2): 431-40.
18) Krishnaswami S:The relavence of lipids in Indians.Lipid India 1996;1:5-7.
19) Das S : Lipidograms in Indian population groups.Lipid India.1996;1:8-11.
20) Mohan V, Shastry N G: Hyperlipidemia in South Indian patients with non-insulin dependent diabetes mellitus:Lipid India.1998.P10-14.
21) Velho G, Erlich D, Turpin E, Neel D, Cohen D, Froguel P et al. Lipo protein (a) in diabetic patients and normoglycemic relatives in familial NIDDM. Diabetes care 1993; 16 : 742 - 747.
22) Timothy O'Brien, Nguyen T, Jay M Harrison, Kent .R. Baitey, Peter James Dyek, Benre Kottke. Lipids and Lp (a) lipoprotein levels and coronary artery disease in subjects with non-insulin dependent diabetes mellitus. Mayo Clini Proc 1994 : 430 - 435.
23) Prasanna BM, Rajalakshmi S, Mala Dharmalingam,Prasannakumar KM; Impaired Glucose Tolerance and lipid profile: Lipid India.96 P18-19.
24) Haffner et al. Cardiovascular risk factors in confirmed pre diabetic individuals,does the clock for CAD start ticking before the onset of clinical diabetes? JAMA 1990:263;2893-98.
25) Davies M,Rayman G,Day J.Increased incidence of CAD in people with impaired glucose tolerance: Link with increased Lp(a) concentrations? BMJ 1992;304;1610-1611.
26) Rhoads GG, Dahlen G, Berg K, Morton NE, Dannen Berg AL. Lp (a) lipoprotein as an independent risk factor for myocardial infarction. JAMA. 1986. 256 : 2540 - 4.
27) Peter .O.Kwiterovich Jr. et al comparison of plasma levels of Apo lipoproteins B and A1 and other risk factors in men and women with premature CAD, Am J Cardiol 1992, 69 : 1015 - 1021.
28) Sedlis et al, plasma apo lipoproteins and severity of CAD - Circulation 1986 : 73.
29) West KM et al. The role of circulating glucose and triglycerides concentration and their interactions with other risk factors or determinants of arterial disease in nine diabetic population samples from WHO multinational study. Diabetes care 6 : 361 - 369, 1983.
30) Galanis et al. Relations of body fat and fat distribution to the serum lipid, apo lipoprotein and insulin concentration of samoan men and women. Int-J-Obes-Relat-Metab-Disorder 1995, Oct: 19 (10) : 731 - 8.
31) Haffner SM, Tuttle KR, Bruton L et al : Lack of change of Lp (a) concentration with improved glycemic control in subjects with type 2 DM. Metabolism.
32) Brewer HB. Effectiveness of diet and drugs in the treatment of patients with elevated lipoprotein (a) levels. Im: Scanu AM. Lipoprotein (a). New York Academic Press, 1990 : 211 - 20.
33) Cox et al. Individual variation in plasma cholesterol response to dietary saturated fat BMJ 1995 Nov 11 : 311 (7015) 1260 - 4.
34) Gascon A et al, plasma lipo protein profile and lipolytic activities in response to the substitution of lean white fish for other animal protein sources in pre-menopausal women. Am J Clin - Nutr 1996 March 63 (3) : 315 - 21.
35) Lam KS et al. Cholesterol lowering therapy may retard the progression of diabetic nephropathy. Diabetologia. May 1995 : 38 (5) : 604 - 9.
36) Low PS, Heng CK, Saha N, Tay JSH. Racial variation of cord plasma Lp (a) levels in relation to coronary risk level, a study in three ethnic groups in Singapore. Pediatr Res 40 : 718 - 722, 1996.
37) Hughes K, Aw TC, Kuperan P, Chao M. Central obesity, insulin resistance, syndrome X, Lipo protein (a) and cardiovascular complications in Indians, Malays and Chinese in Singapore. J Epidermiol Community health. 51 : 394 - 399, 1997.
38) McKeigue PM, Miller GJ Marmot MG : CAD in South Asian Overseas, a review. J Clin Epidermiol 41 : 597 - 598, 1989.
39) Anand SS, Enas EA, Pogue J, Haffner S, Pearson T, Yusuf S. Elevated Lipo protein (a) levels in South Asians in N. America. Metabolism 47 : 182 - 184, 1998.
40) Utermann G. The mysteries of Lipo protein (a). Science 1989; 246 : 904 - 10.
41) Klausen IC, Gerdes LU, Schmidt EB, Dyerberg J, Faergemano. Differences in apo lipoprotein (a) polymorphism in West Greenland Eskimos and Caucasian Danes. Hum Genet; 1992 : 89, 348 - 8.
42) Berg K. Genetics of coronary heart disease. In : Steinberg AC. Bearn AG. Childs B eds. Progress in medical genetics. Philadelphia : WB Saunders : 1983 : 35 - 90.
43) Berg K. Level genes and variability genes in the etiology of hyper lipidemia and atherosclerosis In : Berg K, Refsum S. eds : From phenotype to gene in common disorders. Copenhagen : 1990 : 77 - 91.
44) Loscalzo J. Lp (a) and the fibrinolytic system. In : Scanu AM eds. Lp (a) San Diego : Academic Press 1990 : 75 - 85.
45) Mbewu AD, Durrington PN, Lipo protein (a), structure properties and possible involvement in thrombogenesis and atherogenesis. Atherosclerosis 1990; 85 : 1 - 14.
46) Boerwinkle E, Leffer CC, Lim J et al. Apo lipoprotein (a) gene accounts for greater than 90% of the variation plasma Lp (a) concentrations. J Clin invest. 1992; 90 : 52 - 60.
47) Durington PH, Ishola M, Hunt L, Arrols, Bhatnagar D. Apo lipoprotein (a), A and B and parental history in men with early onset ischemic heart d/s. Lanert 1998 : 1 : 1070 - 3.
48) Berg K. Lipo protein (a) an overview. In : Scanu Am (ed) Lipo protein (a) San Diego : Academic Press 1990 : 1 - 23.
49) Rifai N, Heiss G, Doestsch K. Lp (a) at birth in blacks and whites. Atherosclerosis 1992; 92 : 123 - 129.
50) Dahlen CG. Lipoprotein (a) in cardio vascular disease, review article and view point. Atherosclerosis 1994; 108 : 111 - 126.
51) Lawn RM. Lipo protein (a) in heart disease. Sci Am. 1992; 266 : 54 - 60.
52) Enas EA. Cooking Oil, Cholesterol and CAD. J. Am. Assoc. Physicians Indian Origin. 1996; 8 : 37 - 39.
53) Lackner C, Boerwinkle E, Leffert CC et al. Molecular basis of apo (a) isoform, size, heterogenecity as revealed by pulsed-field gel electrophoresis. J. Clin Invest. 1991l; 87 : 2153 - 2161.
54) Scanu Am. Fless GM. Lipo protein (a) : hetero genecity and biological relevance. J. Clin. Invest : 1990; 85 : 1709 - 15.
55) Scanu Am. Scandiani L : Lipoprotein (a) : Structure, biology and clinical relevance. In : Stollermann GH. Ed. Mosby year book. St. Louis : Mosby : 1991 : 249 - 70.
56) Grainger DJ, Metacalfe JC. Transforming growth factor - beta : the key to understanding lipoprotein (a) curr opin lipidol 1995; 6 : 81 - 5.
57) Shashank R. Lipoprotein (a), review article : Indian practitioner 51 : 1998.
58) Maher VMG, Brown BG, Marcovina SM et al. Effects of lowering elevated LDL Cholesterol on the cardiovascular risk of lipoprotein (a). JAMA 1995, 274 : 1771 - 1774.
59) Solymoss BC, Marcil M, Wesolowska E et al. Relation of coronary artery disease in women 60 years of age to the combined elevation of serum lipo protein (a) and total cholesterol to HDL cholesterol ratio. Am. J. Cardiol 1993; 72 : 1215 - 1219.
60) Bolibar I, Thompson SG, Edkardstein AV et al. Dose response relationships of serum lipid measurements with the extent of coronary stenosis. Arterioscle Thromb Vasc Biol 1995; 15 : 1035 - 1042.
|
|
